Suppressive effect of topical moxifloxacin on imiquimod-induced model of psoriasis in mice
Naunyn-Schmiedeberg's Archives of Pharmacology · 2025-12 · 398 (12) · 17089-17108
DOI: 10.1007/s00210-025-04317-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 03.06.2025. Verfasst von Alaa Hamza Abbas und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, College of Pharmacy, Al-Mustaqbal University, 51001, Hillah, Babylon, Iraq. alla1979200713@yahoo.com. Hauptthemen laut MEDLINE: Moxifloxacin, Psoriasis, Fluoroquinolones, Anti-Inflammatory Agents. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 224 Literaturangaben.
Abstract (Originalsprache)
Psoriasis is a chronic inflammatory skin disorder that is triggered by immune-mediated, genetic, and environmental factors. Moxifloxacin is a fluoroquinolone antibiotic with extended non-expected anti-inflammatory and immune-modulating effects. This study aims to investigate the possible influence of two different concentrations of moxifloxacin emulgel on psoriasis induced via imiquimod in mice. Dividing 48 mice into six groups (8 mice for each group), all groups gated imiquimod to induce psoriasis (except group I) for 7 days. The induction group (Group II) received imiquimod cream for 7 days. The vehicle group obtained emulgel base for 7 days. The rest of the groups got calcipotriol 0.005% ointment, moxifloxacin 3% emulgel, and moxifloxacin 5% emulgel, respectively, once daily for a further 7 days after the induction period. Topical moxifloxacin had important anti-psoriatic activity by diminishing the Psoriasis Area Severity Index (PASI) scores and improving histological alterations during imiquimod application. Moreover, moxifloxacin significantly lowered the levels of inflammatory biomarkers like TGF-β, TNF-α, IL-17, IL-1β, IL-23, and VEFG while increasing levels of anti-inflammatory biomarkers IL-10 and IL-37. Moxifloxacin also suppressed oxidative indicators such as MDA and elevated antioxidant enzyme levels, such as catalase. Moxifloxacin has substantial anti-psoriatic action against imiquimod-induced psoriasis through its anti-proliferative and anti-inflammatory effects. Furthermore, moxifloxacin has a restorative effect on the histopathological alterations of mice's skin induced by imiquimod.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, College of Pharmacy, Al-Mustaqbal University, 51001, Hillah, Babylon, Iraq. alla1979200713@yahoo.com.
- Department of Applied Embryology, High Institute for Infertility Diagnosis and Assisted Reproductive Technologies, Al-Nahrain University, Baghdad, Iraq.
- Department of Pharmacology, College of Pharmacy, Al-Mustaqbal University, 51001, Hillah, Babylon, Iraq.
- College of Pharmacy, Al-Esraa University, Baghdad, Iraq.
- Diwaniyah Health Directorate, Ministry of Health, Diwaniyah, Iraq.
Zitieren
APA
Abbas, A. H., Abbood, M. S., Ridha-Salman, H., Fakhri, S. A., Abbas, Z. H., & Al-Athari, A. J. H. (2025). Suppressive effect of topical moxifloxacin on imiquimod-induced model of psoriasis in mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 398(12), 17089-17108. https://doi.org/10.1007/s00210-025-04317-2
Vancouver
Abbas AH, Abbood MS, Ridha-Salman H, Fakhri SA, Abbas ZH, Al-Athari AJH. Suppressive effect of topical moxifloxacin on imiquimod-induced model of psoriasis in mice. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025;398(12):17089-17108. doi:10.1007/s00210-025-04317-2
BibTeX
@article{Abbas2025,
author = {Abbas, Alaa Hamza and Abbood, Muayad Sraibet and Ridha-Salman, Hayder and Fakhri, Salar Ayad and Abbas, Zahraa Hamza and Al-Athari, Ali Jihad Hemid},
title = {Suppressive effect of topical moxifloxacin on imiquimod-induced model of psoriasis in mice},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2025},
volume = {398},
number = {12},
pages = {17089--17108},
doi = {10.1007/s00210-025-04317-2}
}
EUVIMED